annb0t
Top 20
uniQure Inc.
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylactic therapy and
generate elevated and sustained factor IX levels for years after a one-time infusion ~
~ 18-month data support the ongoing benefit of HEMGENIX® ~
~ HEMGENIX® is approved for adults with hemophilia B in the United States,
European Union and European Economic A...
>>> Read more: uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
~ Data follow the historic approval of the first gene therapy for hemophilia B, which has been shown in clinical trials to reduce the rate of annual bleeds, reduce or eliminate the need for prophylactic therapy and
generate elevated and sustained factor IX levels for years after a one-time infusion ~
~ 18-month data support the ongoing benefit of HEMGENIX® ~
~ HEMGENIX® is approved for adults with hemophilia B in the United States,
European Union and European Economic A...
>>> Read more: uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)
